3 news items
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
DAWN
18 Jun 24
the investigational new drug (IND) application for MTX-13, which going forward will be identified as DAY301. In pre-clinical studies, DAY301 showed antitumor
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
continues in the Phase 1b/2 substudy (102b) of the FIRELIGHT-1 trial evaluating the combination of tovorafenib with the Company's investigational MEK
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
, including patients and their families, study investigators, non-profit organizations, and advocacy groups, for their collaboration and support as we strive
- Prev
- 1
- Next